HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: JME-08-0162v1 42/5/361    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferone, D. Articles by Minuto, F. Search for Related Content PubMed PubMed Citation Articles by Ferone, D. Articles by Minuto, F.

D Ferone, Dept of Endocrinology and Medical Sciences and Center of Excellence for Biomedical Research, University of Genova, Genova, Italy
F Gatto, Dept of Endocrinology and Medical Sciences, University of Genova, Genova, Italy
M Arvigo, Dept of Endocrinology and Medical Sciences and Center of Excellence for Biomedical Research, University of Genova, Genova, Italy
E Resmini, Dept of Endocrinology and Medical Sciences, University of Genova, Genova, Italy
M Boschetti, Dept of Endocrinology and Medical Sciences, University of Genova, Genova, Italy
C Teti, Genova, Italy
D Esposito, Dept of Endocrinology and Medical Sciences, University of Genova, Genova, Italy
F Minuto, Genova, Italy

Correspondence: Diego Ferone, Email: ferone{at}unige.it

Abstract

The role of somatostatin and dopamine receptors as molecular targets for the treatment of patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin receptor agonists are considered miles stones for the medical therapy of these tumours. However, in recent years, the knowledge of the expression of subtypes of somatostatin and dopamine receptors in pituitary adenomas, as well as of the co-expression of both types of receptors in tumour cells, has increased considerably. Moreover, recent insights suggest a functional interface of dopamine and somatostatin receptors, when co-expressed in the same cells. This interaction has been suggested to occur via dimerization of these G-protein coupled receptors. In addition, there was renewed interest around the concept of cell specificity in response to ligand-induced receptor activation. New experimental drugs, including novel somatostatin analogs, binding to multiple somatostatin receptor subtypes, as well as hybrid somatostatin-dopamine compounds have been generated, and recently a completely novel class of molecules has been developed. These advances have opened new perspectives for the medical treatment of patients with pituitary tumours poorly responsive to the current clinically available drugs, and perhaps also for the treatment of other categories of neuroendocrine tumours.

The aim of the present review is to summarize the novel insights in somatostatin and dopamine receptor pathophysiology, and to bring these new insights into perspective for the future strategies in the medical treatment of patients with pituitary adenomas.

This article has been cited by other articles:

				M. C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, M. R. Ambrosio, M. Lapparelli, M. Scanarini, and E. C. degli Uberti Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 968 - 976. [Abstract] [Full Text] [PDF]